Navigation Links
Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
Date:9/30/2013

SAN FRANCISCO, Sept. 30, 2013 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) reported today that AstraZeneca announced that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) for Naloxegol, an investigational peripherally-acting mu-opioid receptor antagonist, which has been specifically designed for the treatment of opioid-induced constipation (OIC) for adult patients 18 years and older, including patients with inadequate response to laxatives.

The MAA filing was based on comprehensive data from the core Phase III KODIAC programme, comprised of four clinical trials designed to investigate the safety and efficacy of naloxegol for the treatment of OIC. Two pivotal Phase III studies, KODIAC-04 (n=652) and KODIAC-05 (n=700), both 12-week, multicentre, randomised, double blind, placebo-controlled pivotal trials evaluated 12.5 mg and 25 mg doses of naloxegol, administered once-daily. KODIAC-07 was a 12-week safety extension of KODIAC-04, and KODIAC-08 (n= 534) was an open-label, randomised, 52-week, long-term safety trial.

Naloxegol has the potential to be the first once-daily oral peripherally-acting mu-opioid receptor antagonist medication for patients with OIC. Naloxegol was developed using Nektar's oral small molecule polymer conjugate technology.

Naloxegol is part of the exclusive worldwide license agreement announced on 21 September 2009, between AstraZeneca and Nektar Therapeutics. Under the terms of the recently amended License Agreement, AstraZeneca will pay Nektar a $25 million milestone within five business days of acceptance of the MAA by the EMA.

NOTES TO EDITORS

About Opioid-Induced Constipation
OIC is a condition caused by prescription opioid pain medicines. Opioids bind to specific proteins called opioid receptors. When the opioids bind to certain opioi
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
2. Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets
3. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
4. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
5. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
6. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
7. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the Jefferies 2013 Global Healthcare Conference in New York City
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
9. Nektar Therapeutics Reports Financial Results for the First Quarter of 2013
10. Nektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets
11. Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... and FARMINGTON, Conn. , ... MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific ... significant unmet medical need and commercial potential, today ... placement of Series E warrants to purchase 21,917,808 ... warrants to purchase 2,191,781 shares of its common ...
(Date:7/6/2015)... , July 6, 2015  Impax Laboratories, Inc. ... Hsu , Ph.D. has resigned from the Company,s Board ... Dr. Hsu was a co-founder of Impax in 1995 ... Officer from October 2006 until April 2014. ... Wilkinson , Impax,s President and Chief Executive Officer stated, ...
(Date:7/6/2015)... DIEGO , July 6, 2015  OncoSec Medical ... DNA-based intratumoral cancer immunotherapies, today announced the appointment of ... position of Vice President of Market Development, effective July ... responsible for evaluating, designing, and executing on the company,s ... "I,m very excited to welcome Joann to ...
Breaking Medicine Technology:Palatin Technologies Completes $30 Million Financing 2Palatin Technologies Completes $30 Million Financing 3Palatin Technologies Completes $30 Million Financing 4Palatin Technologies Completes $30 Million Financing 5Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 2Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 3Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 4Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 5OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development 2OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development 3
... production, increasing blood ... flow, muscle oxygen supply, HOBOKEN, N.J., Oct. ... Hypertension Research reveals Pycnogenol(R),(pic-noj-en-all), an antioxidant plant extract from the bark ... oxide,(NO) production which leads to an increase in blood flow and ...
... Developed Through Joint Venture Between Bristol-Myers Squibb, ... Its Kind in HIV Treatment -, PRINCETON, ... Bristol-Myers Squibb Company (NYSE: BMY ) and ... that Health Canada has approved ATRIPLA(R),(efavirenz 600 mg/emtricitabine ...
Cached Medicine Technology:New Study: Pine Bark Extract Boosts Nitric Oxide (NO) Production 2New Study: Pine Bark Extract Boosts Nitric Oxide (NO) Production 3Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 2Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 3Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 4Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 5Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 6Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 7Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 8Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 9
(Date:7/5/2015)... (PRWEB) , ... July 06, 2015 , ... ... ancillary benefits market, is excited to announce the next generation of PrimeStar Individual ... Advantage plans to now include two network options—Maximum Allowable Charge (MAC) and usual, ...
(Date:7/5/2015)... ... 05, 2015 , ... Doctors at the Swedish Cancer Institute in Seattle, Washington ... change the outlook for people with pleural mesothelioma. Surviving Mesothelioma has just posted the ... that five mesothelioma patients treated with 25Gy of radiation over five days just prior ...
(Date:7/4/2015)... California (PRWEB) , ... July 04, 2015 , ... ... earned the solar industry’s leading recognition of technical sales expertise from the North ... PV Technical Sales ProfessionalTM. NABCEP is the most highly respected and well established ...
(Date:7/3/2015)... ... ... at several top US cancer centers believe they now know why certain people are ... the complete story , just posted on the Surviving Mesothelioma website. , Researchers ... University exposed mice with a mutation on the tumor suppressor gene called BAP1 to ...
(Date:7/3/2015)... ... 03, 2015 , ... Smoothies are all the rage right now and all ... quality ingredients. Aurora Natural is proud to introduce a new line of all natural ... antioxidants, vitamins and minerals! , Aurora is offering a variety of blends and stand-alone ...
Breaking Medicine News(10 mins):Health News:Security Life Insurance Company of America Launches the Next Generation of PrimeStar Individual Dental Insurance Plans 2Health News:New Mesothelioma Study Calls IMRT/Surgery Combo “Innovative and Promising”, According to Surviving Mesothelioma 2Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 2Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 3Health News:Study Finds Small Amounts of Asbestos May Trigger Mesothelioma in People with Genetic Mutation, According to Surviving Mesothelioma 2Health News:Aurora Product, Inc. Announces An Original New Line: Smoothie Fixins’ 2
... donor egg availability and lower cost, innovative IVF financing options ... more couples from the United Kingdom are crossing the ocean ... www.shadygrovefertility.com ), the Washington/Baltimore area,s largest in ... five dozen British patients received IVF treatment there last year, ...
... Take Basic Preparedness Steps for Hurricane and Flu Seasons , ... people were affected by disaster than any year in the previous ... the next six months, as the United States and the Caribbean ... flu, response organizations are preparing for the possibility of an even ...
... Genomics Research Institute (TGen) scientists have identified five genetic ... fewer side-effects, for patients with diabetes. TGen Senior ... Orleans on June 6, 2009, at the 69th Scientific ... genetic variants that may predict how well someone will ...
... Serves Growing Non-Urban Market Segments , , ... ("Global Med" or the "Company") (OTC Bulletin Board: ... announced that its Wyndgate Technologies(R) division has licensed ... 40+ hospital healthcare system. The organization will ...
... ORANGE, Fla., June 16 Suddenly it happens, with the ... ourselves needing to parent our parents. , , Author ... Dance Again," ( published by iUniverse ), encounters ... experience becoming caretaker for her mother, "She Just Wanted to ...
... U.S. Pharma can learn from its counterparts in Europe ... While President Obama,s push for a larger government role ... care model developing in the United States may worry some ... growing influence of payers over physician prescription decisions in the ...
Cached Medicine News:Health News:A Growing Number of Brits Cross the Atlantic for Donor Egg IVF Treatment at Shady Grove Fertility Center 2Health News:A Growing Number of Brits Cross the Atlantic for Donor Egg IVF Treatment at Shady Grove Fertility Center 3Health News:Red Cross, CDC Ready Country for Emergency Threats 2Health News:TGen and USC researchers find genetic markers to help fight diabetes 2Health News:TGen and USC researchers find genetic markers to help fight diabetes 3Health News:Global Med Technologies(R) Licenses Transfusion Software Solution to Nationwide Healthcare System 2Health News:Global Med Technologies(R) Licenses Transfusion Software Solution to Nationwide Healthcare System 3Health News:'She Just Wanted to Dance Again': Navigate the Exchange of Parent-Caregiving Relationships Through Example, Advice 2Health News:Health Care Reform May Force U.S. Pharmaceutical Companies to Overhaul Sales Strategies, Says New Report From ZS Associates and eyeforpharma 2Health News:Health Care Reform May Force U.S. Pharmaceutical Companies to Overhaul Sales Strategies, Says New Report From ZS Associates and eyeforpharma 3Health News:Health Care Reform May Force U.S. Pharmaceutical Companies to Overhaul Sales Strategies, Says New Report From ZS Associates and eyeforpharma 4Health News:Health Care Reform May Force U.S. Pharmaceutical Companies to Overhaul Sales Strategies, Says New Report From ZS Associates and eyeforpharma 5
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Inquire...
Medicine Products: